AFFY Share Price

Open 0.05 Change Price %
High 0.05 1 Day 0.00 0.00
Low 0.05 1 Week 0.00 0.00
Close 0.05 1 Month 0.00 0.00
Volume 3076 1 Year -0.05 -50.00
52 Week High 0.10
52 Week Low 0.00
AFFY Important Levels
Resistance 2 0.05
Resistance 1 0.05
Pivot 0.05
Support 1 0.05
Support 2 0.05
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
SIRI 5.07 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
NASDAQ USA Top Gainers Stocks
ESSX 0.22 69.23%
MYRX 0.08 60.00%
CGEI 0.35 59.09%
LOCM 0.09 50.00%
RITT 0.03 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CARV 4.90 22.81%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%

Affymax, Inc. (NASDAQ: AFFY)

AFFY Technical Analysis 4
As on 21st Apr 2017 AFFY Share Price closed @ 0.05 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.07 & Sell for SHORT-TERM with Stoploss of 0.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
AFFY Target for April
1st Target up-side 0.08
2nd Target up-side 0.11
3rd Target up-side 0.13
1st Target down-side 0.02
2nd Target down-side -0.01
3rd Target down-side -0.03
AFFY Other Details
Segment EQ
Market Capital 814314560.00
Sector Healthcare
Industry Biotechnology
Offical website
AFFY Address
19200 Stevens Creek Boulevard
Suite 240
Cupertino, CA 95014
United States
Phone: 650-812-8700
AFFY Latest News
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...   Business Wire (press release)   - 27th Nov 14
Affymax To Pay $6.5M To End Class Action Over Anemia Drug   Law360 (subscription)   - 04th Jul 14
Affymax Board Announces Decision to Dissolve the Company   Business Wire (press release)   - 25th Jun 14
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner   HotStocked   - 17th Jun 14
Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen   Seeking Alpha   - 28th Aug 13
How to Protect Your Retirement Plans   Benzinga   - 26th Jun 13
Affymax CEO steps down as restructuring firm steps in   San Francisco Business Times (blog)   - 15th May 13
Affymax stock plunges 85 percent on drug recall   Reuters   - 26th Feb 13
(peginesatide) Injection with Fresenius Medical Care North America   Business Wire (press release)   - 12th Jul 12
Affymax, Inc. (NASDAQ:AFFY) Stock Shoots Up   HotStocked   - 09th Aug 10
Interactive Technical Analysis Chart Affymax, Inc. ( AFFY NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Affymax, Inc.
AFFY Business Profile
Affymax, Inc., incorporated on July 20, 2001, is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis. Peginesatide is a synthetic peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a worldwide collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited (Takeda). As of December 31, 2011, over 2,600 patients have received peginesatide in clinical trials. As of December 31, 2011, The New Drug Application (NDA) for peginesatide is under review by the United States, Food and Drug Administration (FDA). As of December 31, 2011, the Company has suspended its development efforts to treat anemia in non-dialysis patients and chemotherapy-induced anemia. The Company and Takeda Pharmaceutical Company Limited completed multiple Phase I and Phase II clinical trials of peginesatide at sites in the United States and the European Union in normal healthy volunteers, dialysis patients, non-dialysis patients and peritoneal dialysis patients. These Phase I clinical trials were designed primarily to demonstrate bioavailability or bioequivalence of product concentrations and formulations while these Phase II trials were designed to determine the safety, pharmacodynamics and pharmacokinetics of peginesatide when administered to patients suffering from anemia. Two of these Phase II clinical trials were conducted to evaluate the use of peginesatide to treat anemic patients in additional segments of the chronic kidney disease patient population. One of the studies focused on evaluating peginesatide in patients undergoing peritoneal dialysis, a special form of dialysis that allows the process to be performed in the patient's home.Another trial was designed to evaluate the conversion of Aranesp-treated chronic kidney disease patients (on dialysis and not on dialysis) to once-monthly peginesatide. As of December 31, 2011, the Company continues to conduct an ongoing Phase II clinical trial of peginesatide in a small number of patients with pure red cell aplasia (PRCA) in European Union.